JP2018537507A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018537507A5 JP2018537507A5 JP2018531575A JP2018531575A JP2018537507A5 JP 2018537507 A5 JP2018537507 A5 JP 2018537507A5 JP 2018531575 A JP2018531575 A JP 2018531575A JP 2018531575 A JP2018531575 A JP 2018531575A JP 2018537507 A5 JP2018537507 A5 JP 2018537507A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- subject
- composition according
- administered
- years old
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 9
- LQUNNCQSFFKSSK-UHFFFAOYSA-N 2-(4-tert-butylphenyl)-1h-benzimidazole Chemical compound C1=CC(C(C)(C)C)=CC=C1C1=NC2=CC=CC=C2N1 LQUNNCQSFFKSSK-UHFFFAOYSA-N 0.000 claims 1
- 206010012289 Dementia Diseases 0.000 claims 1
- 208000036110 Neuroinflammatory disease Diseases 0.000 claims 1
- 230000003542 behavioural effect Effects 0.000 claims 1
- 210000004556 brain Anatomy 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 230000006371 metabolic abnormality Effects 0.000 claims 1
- 210000000274 microglia Anatomy 0.000 claims 1
- 230000003959 neuroinflammation Effects 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 238000007910 systemic administration Methods 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562267437P | 2015-12-15 | 2015-12-15 | |
| US62/267,437 | 2015-12-15 | ||
| PCT/US2016/065972 WO2017106050A1 (en) | 2015-12-15 | 2016-12-09 | Method for preventing and/or treating aging-associated cognitive impairment and neuroinflammation |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018537507A JP2018537507A (ja) | 2018-12-20 |
| JP2018537507A5 true JP2018537507A5 (enExample) | 2020-08-27 |
| JP6837486B2 JP6837486B2 (ja) | 2021-03-03 |
Family
ID=59057428
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018531575A Active JP6837486B2 (ja) | 2015-12-15 | 2016-12-09 | 加齢に関連する認知障害及び神経炎症を予防及び／又は治療する方法 |
Country Status (18)
| Country | Link |
|---|---|
| US (3) | US10653669B2 (enExample) |
| EP (2) | EP3741747B1 (enExample) |
| JP (1) | JP6837486B2 (enExample) |
| KR (1) | KR20180094989A (enExample) |
| CN (1) | CN108884053B (enExample) |
| AU (1) | AU2016371598B2 (enExample) |
| CA (1) | CA3008019A1 (enExample) |
| DK (1) | DK3390367T3 (enExample) |
| ES (1) | ES2830447T3 (enExample) |
| HR (1) | HRP20201652T1 (enExample) |
| HU (1) | HUE051771T2 (enExample) |
| IL (2) | IL285248B2 (enExample) |
| MX (1) | MX379086B (enExample) |
| PL (1) | PL3390367T3 (enExample) |
| PT (1) | PT3390367T (enExample) |
| RS (1) | RS61053B1 (enExample) |
| SM (1) | SMT202000601T1 (enExample) |
| WO (1) | WO2017106050A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016061190A1 (en) | 2014-10-14 | 2016-04-21 | The Board Of Trustees Of The Leland Stanford Junior University | Method for treating neurodegenerative diseases |
| IL285248B2 (en) * | 2015-12-15 | 2025-10-01 | Univ Leland Stanford Junior | It is recommended for use as a drug for the prevention and/or treatment of cognitive impairment associated with aging. |
| KR20210068399A (ko) * | 2018-08-06 | 2021-06-09 | 더 보드 오브 트러스티스 오브 더 리랜드 스탠포드 주니어 유니버시티 | 신경퇴행성 질병의 치료를 위한 피피에이알지씨1알파 활성제로서 2-아릴벤즈이미다졸 |
| CN115916339A (zh) | 2020-06-22 | 2023-04-04 | 特朗奎斯治疗股份有限公司 | 全身免疫激活综合征的治疗 |
| CN112933232A (zh) * | 2021-02-02 | 2021-06-11 | 袁玉佳 | PGC-1α激活TFEB介导的自噬在制备治疗急性肾损伤的药物中的应用 |
| EP4355326A4 (en) * | 2021-06-17 | 2025-04-23 | Tranquis Therapeutics, Inc. | THERAPEUTICALLY EFFECTIVE ORAL ADMINISTRATION OF A 2-ARYL-BENZIMIDAZOLE |
| EP4426295A1 (en) | 2021-11-02 | 2024-09-11 | Tranquis Therapeutics, Inc. | Selection and treatment of subjects having a circulating myeloid cell inflammatory phenotype |
| TW202415372A (zh) | 2022-06-14 | 2024-04-16 | 美商特朗奎斯治療股份有限公司 | 老化相關改變及疾病之治療 |
| TW202416960A (zh) | 2022-06-17 | 2024-05-01 | 美商特朗奎斯治療股份有限公司 | 2-芳基苯并咪唑化合物之調配物 |
| EP4618982A1 (en) * | 2022-11-18 | 2025-09-24 | GOJO, Satoshi | Uses of zln-005 and related compounds |
| WO2024118936A1 (en) | 2022-12-02 | 2024-06-06 | Tranquis Therapeutics, Inc. | 2-arylbenzimidazole compounds for the treatment of hemoglobinopathies |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS53127475A (en) * | 1977-04-07 | 1978-11-07 | Kanebo Ltd | Novel benzimidazole compound and its preparation |
| GB1584296A (en) * | 1976-12-07 | 1981-02-11 | Kanebo Ltd | 2-substituted benzimidazole compounds |
| NZ234564A (en) | 1986-11-21 | 1991-04-26 | Haessle Ab | 1-substituted benzimidazoles and pharmaceutical compositions |
| US5552426A (en) * | 1994-04-29 | 1996-09-03 | Eli Lilly And Company | Methods for treating a physiological disorder associated with β-amyloid peptide |
| CN1331682A (zh) | 1998-11-03 | 2002-01-16 | 巴斯福股份公司 | 取代的2－苯基苯并咪唑类,其制备和用途 |
| BR0107628A (pt) * | 2000-01-14 | 2002-10-08 | Schering Ag | l,2-diarilbenzimidazóis para tratamento de doenças que estão associadas a uma ativação microglial |
| DE10134775A1 (de) * | 2001-07-06 | 2003-01-30 | Schering Ag | 1-Alkyl-2.aryl-benzimidazolderivate, deren Verwendung zur Herstellung von Arzneimitteln sowie diese Derivate enthaltende pharmazeutische Präparate |
| DE10207843A1 (de) * | 2002-02-15 | 2003-09-04 | Schering Ag | Mikrolia-Inhibitoren zur Unterbrechung von Interleukin 12 und IFN-gamma vermittelten Immunreaktionen |
| US20040002524A1 (en) * | 2002-06-24 | 2004-01-01 | Richard Chesworth | Benzimidazole compounds and their use as estrogen agonists/antagonists |
| SE0301371D0 (sv) | 2003-05-09 | 2003-05-09 | Astrazeneca Ab | New Compounds |
| WO2006009736A1 (en) * | 2004-06-17 | 2006-01-26 | Wyeth | Processes for preparing gonadotropin releasing hormone receptor antagonists |
| KR20070057965A (ko) * | 2004-09-21 | 2007-06-07 | 신타 파마슈티칼스 코프. | 염증 및 면역 관련 용도를 위한 화합물 |
| US7689227B2 (en) * | 2005-03-02 | 2010-03-30 | Qualcomm Incorporated | Method and apparatus for hashing over multiple frequency bands in a communication system |
| US7893267B2 (en) * | 2005-03-14 | 2011-02-22 | High Point Pharmaceuticals, Llc | Benzazole derivatives, compositions, and methods of use as β-secretase inhibitors |
| ES2397275T3 (es) | 2005-08-04 | 2013-03-05 | Sirtris Pharmaceuticals, Inc. | Derivados de imidazopiridina como agentes moduladores de la sirtuína |
| GB0807103D0 (en) | 2008-04-18 | 2008-05-21 | Univ Bradford The | Compounds |
| WO2016187217A2 (en) * | 2015-05-18 | 2016-11-24 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and compositions for treating aging-associated impairments |
| GB201009656D0 (en) | 2010-06-09 | 2010-07-21 | Univ St Andrews | Carboxylation catalysts |
| JP6182593B2 (ja) | 2012-04-20 | 2017-08-16 | アドヴィーナス セラピューティクス リミテッド | 置換ヘテロ二環化合物、組成物及び医薬並びにそれらの用途 |
| KR101435496B1 (ko) | 2012-10-22 | 2014-08-28 | 한국과학기술연구원 | 미토콘드리아 기능 조절제로서의 벤즈이미다졸 유도체 |
| WO2014179303A1 (en) * | 2013-04-29 | 2014-11-06 | The General Hospital Corporation | Amyloid precursor protein mrna blockers for treating down syndrome and alzheimer's disease |
| CN113384569A (zh) * | 2013-09-18 | 2021-09-14 | 乔治城大学 | 用非诺贝特及其类似物治疗神经退行性疾病 |
| WO2016061190A1 (en) | 2014-10-14 | 2016-04-21 | The Board Of Trustees Of The Leland Stanford Junior University | Method for treating neurodegenerative diseases |
| CN104873500A (zh) * | 2015-04-29 | 2015-09-02 | 中国人民解放军第四军医大学 | 化合物zln005的用途 |
| IL285248B2 (en) * | 2015-12-15 | 2025-10-01 | Univ Leland Stanford Junior | It is recommended for use as a drug for the prevention and/or treatment of cognitive impairment associated with aging. |
| CN115916339A (zh) * | 2020-06-22 | 2023-04-04 | 特朗奎斯治疗股份有限公司 | 全身免疫激活综合征的治疗 |
-
2016
- 2016-12-09 IL IL285248A patent/IL285248B2/en unknown
- 2016-12-09 RS RS20201363A patent/RS61053B1/sr unknown
- 2016-12-09 EP EP20185530.1A patent/EP3741747B1/en active Active
- 2016-12-09 PT PT168764272T patent/PT3390367T/pt unknown
- 2016-12-09 MX MX2018007147A patent/MX379086B/es unknown
- 2016-12-09 SM SM20200601T patent/SMT202000601T1/it unknown
- 2016-12-09 CN CN201680079142.9A patent/CN108884053B/zh active Active
- 2016-12-09 AU AU2016371598A patent/AU2016371598B2/en active Active
- 2016-12-09 JP JP2018531575A patent/JP6837486B2/ja active Active
- 2016-12-09 ES ES16876427T patent/ES2830447T3/es active Active
- 2016-12-09 HR HRP20201652TT patent/HRP20201652T1/hr unknown
- 2016-12-09 WO PCT/US2016/065972 patent/WO2017106050A1/en not_active Ceased
- 2016-12-09 DK DK16876427.2T patent/DK3390367T3/da active
- 2016-12-09 US US15/781,756 patent/US10653669B2/en active Active
- 2016-12-09 EP EP16876427.2A patent/EP3390367B1/en active Active
- 2016-12-09 PL PL16876427T patent/PL3390367T3/pl unknown
- 2016-12-09 KR KR1020187020017A patent/KR20180094989A/ko not_active Ceased
- 2016-12-09 HU HUE16876427A patent/HUE051771T2/hu unknown
- 2016-12-09 CA CA3008019A patent/CA3008019A1/en active Pending
-
2018
- 2018-06-07 IL IL259902A patent/IL259902B/en unknown
-
2020
- 2020-04-09 US US16/844,414 patent/US20210059985A1/en not_active Abandoned
-
2023
- 2023-11-29 US US18/522,503 patent/US20240245646A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018537507A5 (enExample) | ||
| JP2018021046A5 (enExample) | ||
| JP2017528507A5 (enExample) | ||
| JP2017504611A5 (enExample) | ||
| JP2015083580A5 (enExample) | ||
| JP2017222722A5 (enExample) | ||
| JP2018048154A5 (enExample) | ||
| JP2015057451A5 (enExample) | ||
| JP2007519649A5 (enExample) | ||
| JP2013543896A5 (enExample) | ||
| JP2021152008A5 (enExample) | ||
| JP2018513107A5 (enExample) | ||
| JP2013519675A5 (enExample) | ||
| JP2020512337A5 (enExample) | ||
| JP2010504973A5 (enExample) | ||
| JP2019516735A5 (enExample) | ||
| JP2016027060A5 (enExample) | ||
| JP2017508817A5 (enExample) | ||
| JP2017505293A5 (enExample) | ||
| JP2016510326A5 (enExample) | ||
| MA37455A1 (fr) | Utilisation d'un dérivé de pyrazole dans le traitement d'exacerbations aigues d'une maladie pulmonaire obstructive chronique | |
| JP2016020375A5 (enExample) | ||
| JP2017522300A5 (enExample) | ||
| JP2016537338A5 (enExample) | ||
| JP2013507442A5 (enExample) |